Symptoms of Interstitial Cystitis, Painful Bladder Syndrome and Similar Diseases in Women: A Systematic Review

2007 ◽  
Vol 177 (2) ◽  
pp. 450-456 ◽  
Author(s):  
Laura M. Bogart ◽  
Sandra H. Berry ◽  
J. Quentin Clemens
Keyword(s):  
Systematic Review ◽  
Interstitial Cystitis ◽  
Painful Bladder Syndrome ◽  
Painful Bladder

scholarly journals Systematic Review and Meta-Analysis of Intravesical Hyaluronic Acid and Hyaluronic Acid/Chondroitin Sulfate Instillation for Interstitial Cystitis/Painful Bladder Syndrome

2016 ◽  
Vol 39 (4) ◽  
pp. 1618-1625 ◽  
Author(s):  
Jung-Soo Pyo ◽  
Won Jin Cho
Keyword(s):  
Systematic Review ◽  
Hyaluronic Acid ◽  
Chondroitin Sulfate ◽  
Interstitial Cystitis ◽  
Meta Analysis ◽  
Urine Volume ◽  
Painful Bladder Syndrome ◽  
Pain Symptom ◽  
Bladder Pain ◽  
Painful Bladder

Background/Aims: To assess the efficacy of intravesical hyaluronic acid (HA) and HA/chondroitin sulfate (CS) instillation in patients with interstitial cystitis/painful bladder syndrome by systematic review and meta-analysis. Methods: A systematic literature search was performed using the keywords: ‘interstitial cystitis' or ‘painful bladder syndrome' or ‘bladder pain syndrome' and ‘hyaluronic acid', up to March 31, 2016. The primary outcome was visual analogue scale related pain symptom (VAS). Secondary outcomes were the O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) and Problem Index (ICPI), frequency, nocturia, bladder volume, and voided urine volume. Results: Ten articles involving 390 patients were retrieved and assessed in analysis. A significant improvement in mean VAS on fixed-effect and random-effect models (mean difference [MD] -3.654, 95% confidence interval [CI] -3.814 to -3.495, and MD -3.206, 95% CI -4.156 to -2.257, respectively) was found. Significant improvements were found in the ICSI (MD -3.223, 95% CI -4.132 to -2.315) and ICPI (MD -2.941, 95% CI -3.767 to -2.116). Similarly, the other outcomes were significantly improved. Conclusion: Intravesical HA and HA/CS instillation improved pain symptom, quality of life, and other outcomes and could be included as therapeutic modality of interstitial cystitis/painful bladder syndrome.

scholarly journals A Systematic Review of Mycoplasma and Ureaplasma in Urogynaecology

2017 ◽  
Vol 77 (12) ◽  
pp. 1299-1303 ◽  
Author(s):  
Nina Combaz-Söhnchen ◽  
Annette Kuhn
Keyword(s):  
Systematic Review ◽  
Interstitial Cystitis ◽  
Ureaplasma Urealyticum ◽  
Current Knowledge ◽  
Mycoplasma Hominis ◽  
Painful Bladder Syndrome ◽  
Mycoplasma Species ◽  
Pcr Analysis ◽  
Painful Bladder ◽  
Tract Infections

AbstractMycoplasma species relevant to the urogenital tract include mycoplasma hominis, mycoplasma genitalia and ureaplasma urealyticum. Their occurrence in the context of urogynaecological disease has been demonstrated in urethritis, cystitis and upper renal tract infections. Their role in hyperactive bladder and interstitial cystitis/painful bladder syndrome is controversial. All the above-mentioned microorganisms can occur as commensals or as potential pathogens. In most cases their role in any particular pathology cannot be proven, only presumed. The aim of this systematic review was to summarise current knowledge on the influence of mycoplasma and ureaplasma in urogynaecological pathology and to provide clinical guidance on diagnosis (when and how is pathogen detection indicated?) and treatment. 377 relevant articles were analysed. In summary: a urethral swab for PCR analysis of the three bacteria should be performed in the context of symptomatic sterile leukocyturia, chronic urethritis and suspected hyperactive bladder or interstitial cystitis/painful bladder syndrome. Symptomatic women should be treated strictly according to results of the antibiogram.

Sign in / Sign up

Export Citation Format

Share Document